Irish life sciences company Malin Corporation has acquired 33% stake in Wren Therapeutics with the aim of developing rational therapeutic strategies.
The target company is a UK-based biopharmaceutical organisation that is a spin out from the University of Cambridge, UK, and Lund University, Sweden.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition terms also give Malin an option to increase its shareholding in Wren Therapeutics to 67%.
Eli Lilly and Company has reached an agreement to acquire a biopharmaceutical company named CoLucid Pharmaceuticals with the aim of enhancing its existing portfolio in migraine pain management and adding a potential near-term launch to its late-stage pipeline.
The acquisition is being executed through a tender offer and includes a purchase consideration of up to $960m.
Both companies involved in the acquisition are based in the US. The transaction is expected to be completed by the end of the first quarter of 2017.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
